JP2010531878A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010531878A5 JP2010531878A5 JP2010514839A JP2010514839A JP2010531878A5 JP 2010531878 A5 JP2010531878 A5 JP 2010531878A5 JP 2010514839 A JP2010514839 A JP 2010514839A JP 2010514839 A JP2010514839 A JP 2010514839A JP 2010531878 A5 JP2010531878 A5 JP 2010531878A5
- Authority
- JP
- Japan
- Prior art keywords
- human
- pharmaceutical composition
- derivative
- cancer cells
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US93747107P | 2007-06-27 | 2007-06-27 | |
| PCT/US2008/008084 WO2009002562A2 (en) | 2007-06-27 | 2008-06-27 | Complexes of il-15 and il-15ralpha and uses thereof |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014001373A Division JP2014114294A (ja) | 2007-06-27 | 2014-01-08 | ＩＬ‐１５とＩＬ‐１５Ｒαとの複合体及びその使用 |
| JP2015115431A Division JP2015212270A (ja) | 2007-06-27 | 2015-06-08 | ＩＬ‐１５とＩＬ‐１５Ｒαとの複合体及びその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010531878A JP2010531878A (ja) | 2010-09-30 |
| JP2010531878A5 true JP2010531878A5 (enExample) | 2011-08-11 |
Family
ID=40186225
Family Applications (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010514839A Pending JP2010531878A (ja) | 2007-06-27 | 2008-06-27 | ＩＬ‐１５とＩＬ‐１５Ｒαとの複合体及びその使用 |
| JP2014001373A Pending JP2014114294A (ja) | 2007-06-27 | 2014-01-08 | ＩＬ‐１５とＩＬ‐１５Ｒαとの複合体及びその使用 |
| JP2015115431A Pending JP2015212270A (ja) | 2007-06-27 | 2015-06-08 | ＩＬ‐１５とＩＬ‐１５Ｒαとの複合体及びその使用 |
| JP2016226503A Withdrawn JP2017079745A (ja) | 2007-06-27 | 2016-11-22 | ＩＬ‐１５とＩＬ‐１５Ｒαとの複合体及びその使用 |
| JP2018245439A Withdrawn JP2019088288A (ja) | 2007-06-27 | 2018-12-27 | ＩＬ‐１５とＩＬ‐１５Ｒαとの複合体及びその使用 |
| JP2021086283A Pending JP2021152017A (ja) | 2007-06-27 | 2021-05-21 | ＩＬ‐１５とＩＬ‐１５Ｒαとの複合体及びその使用 |
| JP2022172896A Pending JP2023015158A (ja) | 2007-06-27 | 2022-10-28 | ＩＬ‐１５とＩＬ‐１５Ｒαとの複合体及びその使用 |
Family Applications After (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014001373A Pending JP2014114294A (ja) | 2007-06-27 | 2014-01-08 | ＩＬ‐１５とＩＬ‐１５Ｒαとの複合体及びその使用 |
| JP2015115431A Pending JP2015212270A (ja) | 2007-06-27 | 2015-06-08 | ＩＬ‐１５とＩＬ‐１５Ｒαとの複合体及びその使用 |
| JP2016226503A Withdrawn JP2017079745A (ja) | 2007-06-27 | 2016-11-22 | ＩＬ‐１５とＩＬ‐１５Ｒαとの複合体及びその使用 |
| JP2018245439A Withdrawn JP2019088288A (ja) | 2007-06-27 | 2018-12-27 | ＩＬ‐１５とＩＬ‐１５Ｒαとの複合体及びその使用 |
| JP2021086283A Pending JP2021152017A (ja) | 2007-06-27 | 2021-05-21 | ＩＬ‐１５とＩＬ‐１５Ｒαとの複合体及びその使用 |
| JP2022172896A Pending JP2023015158A (ja) | 2007-06-27 | 2022-10-28 | ＩＬ‐１５とＩＬ‐１５Ｒαとの複合体及びその使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US9931377B2 (enExample) |
| EP (3) | EP2724728B1 (enExample) |
| JP (7) | JP2010531878A (enExample) |
| AU (1) | AU2008269032B2 (enExample) |
| CA (1) | CA2691785C (enExample) |
| DK (1) | DK2173378T3 (enExample) |
| ES (2) | ES2716476T3 (enExample) |
| HK (1) | HK1198421A1 (enExample) |
| IL (1) | IL202997A (enExample) |
| NZ (4) | NZ703668A (enExample) |
| WO (1) | WO2009002562A2 (enExample) |
Families Citing this family (118)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL1899364T5 (pl) | 2005-05-17 | 2024-12-09 | University Of Connecticut | Kompozycje i sposoby immunomodulacji w organizmie |
| EP1777294A1 (en) | 2005-10-20 | 2007-04-25 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins |
| MX2008007056A (es) | 2005-12-02 | 2008-11-12 | Sinai School Medicine | Virus quimericos que presentan proteinas de superficie no nativas y usos de los mismos. |
| EP1984505B1 (en) | 2006-01-13 | 2019-12-25 | The Government of the U.S.A., as repr. by the Secretary, Dept. of Health & Human Services, the Nat. Inst. of Health | Codon optimized il-15 and il-15r-alpha genes for expression in mammalian cells |
| DK2160401T3 (da) | 2007-05-11 | 2014-10-20 | Altor Bioscience Corp | Fusionsmolekyler og il-15-varianter |
| CA2691785C (en) * | 2007-06-27 | 2017-01-10 | Marine Polymer Technologies Inc. | Complexes of il-15 and il-15ralpha and uses thereof |
| EP3135294B1 (en) | 2009-08-14 | 2020-06-03 | The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services | Use of il-15-il-15 receptor heterodimers to treat lymphopenia |
| CN102821790A (zh) | 2009-09-14 | 2012-12-12 | 宾夕法尼亚大学托管会 | 包含IL-15受体α和/或编码IL-15受体α的核酸分子的疫苗和免疫治疗剂,以及其使用方法 |
| CN101837123B (zh) * | 2010-05-27 | 2016-05-25 | 四川大学 | 肿瘤细胞疫苗及其制备方法 |
| US11053299B2 (en) | 2010-09-21 | 2021-07-06 | Immunity Bio, Inc. | Superkine |
| EP2619229B1 (en) | 2010-09-21 | 2016-04-06 | Altor BioScience Corporation | Multimeric il-15 soluble fusion molecules and methods of making and using same |
| JP2014502258A (ja) | 2010-10-22 | 2014-01-30 | ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド | 免疫反応を抑制するためにプログラムされた制御性ｔ細胞の発見 |
| EP2537933A1 (en) * | 2011-06-24 | 2012-12-26 | Institut National de la Santé et de la Recherche Médicale (INSERM) | An IL-15 and IL-15Ralpha sushi domain based immunocytokines |
| DK2859015T3 (en) * | 2012-06-08 | 2018-06-18 | Alkermes Inc | LIGANDS MODIFIED BY CIRCULAR MODIFICATION AS AGONISTS AND ANTAGONISTS |
| WO2014052545A2 (en) | 2012-09-28 | 2014-04-03 | Dana-Farber Cancer Institute, Inc. | Targeted expansion of qa-1-peptide-specific regulatory cd8 t cells to ameliorate arthritis |
| WO2014066527A2 (en) * | 2012-10-24 | 2014-05-01 | Admune Therapeutics Llc | Il-15r alpha forms, cells expressing il-15r alpha forms, and therapeutic uses of il-15r alpha and il-15/il-15r alpha complexes |
| KR102222157B1 (ko) | 2013-03-14 | 2021-03-03 | 이칸 스쿨 오브 메디슨 엣 마운트 시나이 | 뉴캐슬병 바이러스 및 이의 용도 |
| TWI654206B (zh) | 2013-03-16 | 2019-03-21 | 諾華公司 | 使用人類化抗－ｃｄ１９嵌合抗原受體治療癌症 |
| KR102539359B1 (ko) | 2013-04-19 | 2023-06-02 | 싸이튠 파마 | 감소된 혈관 누출 증후군에 대한 사이토카인 유도체 치료 |
| EP3974520A1 (en) * | 2013-05-14 | 2022-03-30 | Board of Regents, The University of Texas System | Human application of engineered chimeric antigen receptor (car) t-cells |
| SI3030262T1 (sl) * | 2013-08-08 | 2020-03-31 | Cytune Pharma | Kombiniran farmacevtski sestavek |
| CA2919725C (en) | 2013-08-08 | 2023-04-18 | Cytune Pharma | An il-15 and il-15r.aplha. sushi domain based modulokines |
| AU2014377106B2 (en) | 2014-01-08 | 2019-10-03 | Jiangsu Hengrui Medicine Co., Ltd. | IL-15 heterodimeric protein and uses thereof |
| CA3190002A1 (en) | 2014-02-14 | 2015-08-20 | Board Of Regents, The University Of Texas System | Chimeric antigen receptors and methods of making |
| WO2015127501A1 (en) | 2014-02-27 | 2015-09-03 | Viralytics Limited | Combination method for treatment of cancer |
| EP2915569A1 (en) | 2014-03-03 | 2015-09-09 | Cytune Pharma | IL-15/IL-15Ralpha based conjugates purification method |
| EP3593812A3 (en) | 2014-03-15 | 2020-05-27 | Novartis AG | Treatment of cancer using chimeric antigen receptor |
| IL322264A (en) | 2014-04-07 | 2025-09-01 | Novartis Ag | Cancer treatment using chimeric antigen receptor (CAR) against CD19 |
| KR102503476B1 (ko) | 2014-06-30 | 2023-02-24 | 알토 바이오사이언스 코포레이션 | Il-15-베이즈드 분자 및 이의 사용 방법 |
| US9777061B2 (en) | 2014-07-21 | 2017-10-03 | Novartis Ag | Treatment of cancer using a CD33 chimeric antigen receptor |
| MY181834A (en) | 2014-07-21 | 2021-01-08 | Novartis Ag | Treatment of cancer using humanized anti-bcma chimeric antigen receptor |
| WO2016025880A1 (en) | 2014-08-14 | 2016-02-18 | Novartis Ag | Treatment of cancer using gfr alpha-4 chimeric antigen receptor |
| SG11201700770PA (en) | 2014-08-19 | 2017-03-30 | Novartis Ag | Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment |
| ES2891332T3 (es) | 2014-09-17 | 2022-01-27 | Novartis Ag | Direccionamiento a células citotóxicas con receptores quiméricos para la inmunoterapia adoptiva |
| MA41044A (fr) | 2014-10-08 | 2017-08-15 | Novartis Ag | Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer |
| WO2016061142A1 (en) | 2014-10-14 | 2016-04-21 | Novartis Ag | Antibody molecules to pd-l1 and uses thereof |
| US20180334490A1 (en) | 2014-12-03 | 2018-11-22 | Qilong H. Wu | Methods for b cell preconditioning in car therapy |
| LT3235830T (lt) * | 2014-12-19 | 2020-12-28 | Jiangsu Hengrui Medicine Co., Ltd. | Interleukino 15 baltymų kompleksas ir jo naudojimas |
| MX2017012939A (es) | 2015-04-08 | 2018-05-22 | Novartis Ag | Terapias cd20, terapias cd22 y terapias de combinacion con una celula que expresa un receptor quimerico de antigeno (car) de cd19. |
| EP3286211A1 (en) | 2015-04-23 | 2018-02-28 | Novartis AG | Treatment of cancer using chimeric antigen receptor and protein kinase a blocker |
| WO2017019897A1 (en) | 2015-07-29 | 2017-02-02 | Novartis Ag | Combination therapies comprising antibody molecules to tim-3 |
| ES2878188T3 (es) | 2015-07-29 | 2021-11-18 | Novartis Ag | Terapias de combinación que comprenden moléculas de anticuerpos contra LAG-3 |
| EP4378957A3 (en) | 2015-07-29 | 2024-08-07 | Novartis AG | Combination therapies comprising antibody molecules to pd-1 |
| JP2018529753A (ja) * | 2015-10-06 | 2018-10-11 | ザ・ウイスター・インステイテユート・オブ・アナトミー・アンド・バイオロジー | 転移性及び難治性癌及び腫瘍の処置のための方法及び組成物 |
| EP3389712B1 (en) | 2015-12-17 | 2024-04-10 | Novartis AG | Antibody molecules to pd-1 and uses thereof |
| SG11201805162VA (en) * | 2015-12-18 | 2018-07-30 | Oncosec Medical Inc | Plasmid constructs for heterologous protein expression and methods of use |
| PT3393504T (pt) | 2015-12-22 | 2025-12-30 | Novartis Ag | Recetor de antigénio quimérico (car) de mesotelina e anticorpo contra o inibidor de pd-l1 para utilização combinada em terapia anticancerígena |
| CA3016287A1 (en) | 2016-03-04 | 2017-09-08 | Novartis Ag | Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore |
| WO2017172981A2 (en) | 2016-03-29 | 2017-10-05 | University Of Southern California | Chimeric antigen receptors targeting cancer |
| WO2017173367A2 (en) | 2016-03-31 | 2017-10-05 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Extracellular vesicles, methods of making them, and methods of reducing liver uptake of extracellular vesicles |
| EP3443001B1 (en) | 2016-04-11 | 2025-04-30 | Obsidian Therapeutics, Inc. | REGULATED BIOCIRCUIT SYSTEMS |
| EP3458092A1 (en) | 2016-05-18 | 2019-03-27 | Modernatx, Inc. | Mrna combination therapy for the treatment of cancer |
| US11472856B2 (en) | 2016-06-13 | 2022-10-18 | Torque Therapeutics, Inc. | Methods and compositions for promoting immune cell function |
| CN109641947B (zh) | 2016-07-20 | 2023-04-14 | 犹他大学研究基金会 | Cd229 car t细胞及其使用方法 |
| WO2018026872A1 (en) * | 2016-08-01 | 2018-02-08 | Virogin Biotech Canada Ltd | Oncolytic herpes simplex virus vectors expressing immune system-stimulatory molecules |
| WO2018067992A1 (en) | 2016-10-07 | 2018-04-12 | Novartis Ag | Chimeric antigen receptors for the treatment of cancer |
| BR112019007281A2 (pt) | 2016-10-14 | 2019-07-09 | Xencor Inc | proteína heterodimérica, composições de ácido nucleico e de vetor de expressão, vetor de expressão, célula hospedeira, e, métodos para produzir proteína heterodimérica e para tratar câncer em um paciente |
| KR102392142B1 (ko) | 2016-10-21 | 2022-04-28 | 알토 바이오사이언스 코포레이션 | 다량체 il-15 기반 분자 |
| CA3049652A1 (en) | 2017-01-10 | 2018-07-19 | Intrexon Corporation | Modulating expression of polypeptides via new gene switch expression systems |
| US11629340B2 (en) | 2017-03-03 | 2023-04-18 | Obsidian Therapeutics, Inc. | DHFR tunable protein regulation |
| CN110831961B (zh) | 2017-03-03 | 2024-01-02 | 黑曜石疗法公司 | 用于免疫疗法的cd19组合物和方法 |
| US10743996B2 (en) * | 2017-03-24 | 2020-08-18 | Robert L. Bundy | Amnion putty for cartilage repair |
| US11344578B2 (en) | 2017-04-19 | 2022-05-31 | Board Of Regents, The University Of Texas System | Immune cells expressing engineered antigen receptors |
| AU2018257917B2 (en) | 2017-04-24 | 2023-05-04 | University Of Massachusetts | Diagnosis and treatment of vitiligo |
| US20200179511A1 (en) | 2017-04-28 | 2020-06-11 | Novartis Ag | Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor |
| US20200055948A1 (en) | 2017-04-28 | 2020-02-20 | Novartis Ag | Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor |
| JOP20190256A1 (ar) | 2017-05-12 | 2019-10-28 | Icahn School Med Mount Sinai | فيروسات داء نيوكاسل واستخداماتها |
| WO2018217203A1 (en) | 2017-05-25 | 2018-11-29 | Oreilly Richard John | Use of the il-15/il-15ra complex in the generation of antigen-specific t cells for adoptive immunotherapy |
| CN111225675B (zh) | 2017-06-02 | 2024-05-03 | 朱诺治疗学股份有限公司 | 使用过继细胞疗法治疗的制品和方法 |
| EP3644721A1 (en) | 2017-06-29 | 2020-05-06 | Juno Therapeutics, Inc. | Mouse model for assessing toxicities associated with immunotherapies |
| AU2018291497A1 (en) | 2017-06-30 | 2020-01-16 | Xencor, Inc. | Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15Ra and antigen binding domains |
| KR20210032924A (ko) | 2017-09-05 | 2021-03-25 | 토크 테라퓨틱스, 인코포레이티드 | 치료용 단백질 조성물 및 그의 제조 및 사용 방법 |
| CA3080904A1 (en) | 2017-11-01 | 2019-05-09 | Juno Therapeutics, Inc. | Antibodies and chimeric antigen receptors specific for b-cell maturation antigen |
| US12031975B2 (en) | 2017-11-01 | 2024-07-09 | Juno Therapeutics, Inc. | Methods of assessing or monitoring a response to a cell therapy |
| MX2020004572A (es) | 2017-11-01 | 2020-10-07 | Juno Therapeutics Inc | Receptores de antigenos quimericos especificos para el antigeno de maduracion de celulas b y polinucleotidos que codifican los mismos. |
| WO2019118937A1 (en) | 2017-12-15 | 2019-06-20 | Juno Therapeutics, Inc. | Anti-cct5 binding molecules and methods of use thereof |
| WO2019165121A1 (en) | 2018-02-21 | 2019-08-29 | Board Of Regents, The University Of Texas System | Methods for activation and expansion of natural killer cells and uses therof |
| MX2020009359A (es) * | 2018-03-08 | 2021-01-29 | Rubius Therapeutics Inc | Sistemas de celulas terapeuticas y metodos para el tratamiento de cancer y enfermedades infecciosas. |
| KR20200135986A (ko) * | 2018-03-19 | 2020-12-04 | 멀티비르 인코포레이티드 | 종양 억제인자 유전자 치료 및 cd122/cd132 작용제를 포함하는 암 치료를 위한 방법 및 조성물 |
| WO2019195420A1 (en) * | 2018-04-04 | 2019-10-10 | Nant Holding IP, LLC | Advanced avartar dendritic cells |
| JP7516254B2 (ja) | 2018-04-18 | 2024-07-16 | ゼンコア インコーポレイテッド | Ｉｌ－１５／ｉｌ－１５ｒａヘテロ二量体ｆｃ融合タンパク質およびその使用 |
| JP2021520829A (ja) | 2018-04-18 | 2021-08-26 | ゼンコア インコーポレイテッド | ＩＬ−１５／ＩＬ−１５ＲＡ Ｆｃ融合タンパク質およびＴＩＭ−３抗原結合ドメインを含む、ＴＩＭ−３標的化ヘテロ二量体融合タンパク質 |
| CA3097593A1 (en) | 2018-04-18 | 2019-10-24 | Xencor, Inc. | Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof |
| KR20210003813A (ko) | 2018-04-18 | 2021-01-12 | 젠코어 인코포레이티드 | IL-15/IL-15Rα Fc-융합 단백질 및 LAG-3 항원 결합 도메인을 함유하는 LAG-3 표적화 이종이량체 융합 단백질 |
| EP3784351A1 (en) | 2018-04-27 | 2021-03-03 | Novartis AG | Car t cell therapies with enhanced efficacy |
| WO2019227003A1 (en) | 2018-05-25 | 2019-11-28 | Novartis Ag | Combination therapy with chimeric antigen receptor (car) therapies |
| AU2019284911B2 (en) | 2018-06-13 | 2026-04-09 | Novartis Ag | BCMA chimeric antigen receptors and uses thereof |
| WO2019246392A1 (en) | 2018-06-22 | 2019-12-26 | Cugene Inc. | Cytokine-based bioactivatable drugs and methods of uses thereof |
| CA3102821A1 (en) | 2018-06-22 | 2019-12-26 | Cugene Inc. | Novel interleukin-15 (1l-15) fusion proteins and uses thereof |
| WO2020037215A1 (en) | 2018-08-17 | 2020-02-20 | Icahn School Of Medicine At Mount Sinai | Recombinant newcastle disease viruses and uses thereof for the prevention of rsv disease or human metapneumovirus disease |
| EP3849589A1 (en) * | 2018-09-14 | 2021-07-21 | ModernaTX, Inc. | Methods and compositions for treating cancer using mrna therapeutics |
| WO2020069405A1 (en) | 2018-09-28 | 2020-04-02 | Novartis Ag | Cd22 chimeric antigen receptor (car) therapies |
| US20210347851A1 (en) | 2018-09-28 | 2021-11-11 | Novartis Ag | Cd19 chimeric antigen receptor (car) and cd22 car combination therapies |
| WO2020077180A1 (en) | 2018-10-11 | 2020-04-16 | Nantcell, Inc. | Treatment of immunosuppressed subjects |
| CR20210239A (es) | 2018-10-12 | 2021-12-15 | Xencor Inc | Proteínas de fusión de il-15/il-15ralfa-fc dirigidas a pd-1 y usos de las mismas en terapias combinadas |
| MX2021005022A (es) | 2018-11-01 | 2021-09-08 | Juno Therapeutics Inc | Receptores de antigenos quimericos especificos para el miembro d del grupo 5 de la clase c del receptor acoplado a proteina g (gprc5d). |
| SG11202104188VA (en) | 2018-11-01 | 2021-05-28 | Juno Therapeutics Inc | Methods for treatment using chimeric antigen receptors specific for b-cell maturation antigen |
| EP3880238A1 (en) | 2018-11-16 | 2021-09-22 | Juno Therapeutics, Inc. | Methods of dosing engineered t cells for the treatment of b cell malignancies |
| JP2022513639A (ja) * | 2018-11-29 | 2022-02-09 | ヴァイロジン バイオテック カナダ リミテッド | 低神経毒性ｈｓｖベクター |
| BR112021010354A2 (pt) | 2018-11-30 | 2021-11-03 | Juno Therapeutics Inc | Métodos para o tratamento usando terapia celular adotiva |
| CN113438961A (zh) | 2018-12-20 | 2021-09-24 | Xencor股份有限公司 | 含有IL-15/IL-15Rα和NKG2D抗原结合结构域的靶向异二聚体Fc融合蛋白 |
| CA3123303A1 (en) | 2019-01-29 | 2020-08-06 | Juno Therapeutics, Inc. | Antibodies and chimeric antigen receptors specific for receptor tyrosine kinase like orphan receptor 1 (ror1) |
| US20220226402A1 (en) * | 2019-03-25 | 2022-07-21 | Northshore University Health System | Methods and compositions comprising enhanced targeted immune gene therapy for the treatment of cancer |
| MX2022002747A (es) | 2019-09-10 | 2022-04-06 | Obsidian Therapeutics Inc | Proteinas de fusion de ca2-il15 para regulacion ajustable. |
| TW202128757A (zh) | 2019-10-11 | 2021-08-01 | 美商建南德克公司 | 具有改善之特性的 PD-1 標靶 IL-15/IL-15Rα FC 融合蛋白 |
| WO2021113644A1 (en) | 2019-12-05 | 2021-06-10 | Multivir Inc. | Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer |
| IL297147B1 (en) | 2020-04-10 | 2026-05-01 | Juno Therapeutics Inc | Methods and uses related to engineered cell therapy with a chimeric antigen receptor directed against a B-cell maturation antigen |
| MX2023005609A (es) | 2020-11-13 | 2023-05-29 | Novartis Ag | Terapias de combinacion con celulas que expresan receptores quimericos para el antigeno (car). |
| US11459372B2 (en) | 2020-11-30 | 2022-10-04 | Crispr Therapeutics Ag | Gene-edited natural killer cells |
| US11473060B2 (en) | 2020-12-30 | 2022-10-18 | Crispr Therapeutics Ag | Compositions and methods for differentiating stem cells into NK cells |
| US12234473B2 (en) | 2020-12-31 | 2025-02-25 | Immatics US, Inc. | CD8 polypeptides, compositions, and methods of using thereof |
| EP4314073A4 (en) | 2021-03-24 | 2025-02-19 | Alkermes, Inc. | Upar antibodies and fusion proteins with the same |
| WO2023250400A1 (en) | 2022-06-22 | 2023-12-28 | Juno Therapeutics, Inc. | Treatment methods for second line therapy of cd19-targeted car t cells |
| CN119698301A (zh) | 2022-08-04 | 2025-03-25 | 诺华医药股份公司 | Il-15抑制剂用于治疗特应性皮炎 |
| CN120051298A (zh) | 2022-08-05 | 2025-05-27 | 朱诺治疗学股份有限公司 | Gprc5d和bcma特异性嵌合抗原受体 |
| US20260048099A1 (en) | 2022-08-16 | 2026-02-19 | The United States Of America, As Represented By The Secretary, Deparment Of Health And Human Service | Synergistic interactions for improved cancer treatment |
| WO2024129778A2 (en) | 2022-12-13 | 2024-06-20 | Juno Therapeutics, Inc. | Chimeric antigen receptors specific for baff-r and cd19 and methods and uses thereof |
| WO2025019869A2 (en) * | 2023-07-20 | 2025-01-23 | The Johns Hopkins University | Cell culture medium and compositions thereof |
Family Cites Families (80)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2444713A1 (fr) | 1978-12-18 | 1980-07-18 | Pasteur Institut | Procede de production d'un adn comprenant le genome du virus de l'hepatite b et vecteur le comportant |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4675187A (en) | 1983-05-16 | 1987-06-23 | Bristol-Myers Company | BBM-1675, a new antibiotic complex |
| IL71691A (en) | 1984-04-27 | 1991-04-15 | Yeda Res & Dev | Production of interferon-ypsilon |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| JPS6297624A (ja) | 1985-10-24 | 1987-05-07 | イ−・アイ・デユポン・デ・ニモアス・アンド・カンパニ− | ガス分離法及びその膜 |
| JPS62205784A (ja) | 1986-03-05 | 1987-09-10 | 雪印乳業株式会社 | 新しい型のプラスミノ−ゲン活性化因子の製造方法 |
| US4705540A (en) | 1986-04-17 | 1987-11-10 | E. I. Du Pont De Nemours And Company | Polyimide gas separation membranes |
| US4717393A (en) | 1986-10-27 | 1988-01-05 | E. I. Du Pont De Nemours And Company | Polyimide gas separation membranes |
| US4717394A (en) | 1986-10-27 | 1988-01-05 | E. I. Du Pont De Nemours And Company | Polyimide gas separation membranes |
| US4912197A (en) | 1987-08-14 | 1990-03-27 | E. I. Du Pont De Nemours And Company | Highly soluble clear polyimides |
| US4880442A (en) | 1987-12-22 | 1989-11-14 | E. I. Du Pont De Nemours And Company | Polyimide gas separation membranes |
| US4851505A (en) | 1988-04-13 | 1989-07-25 | E. I. Du Pont De Nemours And Company | Highly soluble aromatic polyimides |
| US4935490A (en) | 1988-04-13 | 1990-06-19 | E. I. Dupont De Nemours And Company | Highly soluble aromatic polyimides |
| US4838900A (en) | 1988-04-13 | 1989-06-13 | E. I. Du Pont De Nemours And Company | Polyimide gas separation membranes |
| US4863496A (en) | 1988-04-13 | 1989-09-05 | E. I. Du Pont De Nemours And Co. | Reactive posttreatment for gas separation membranes |
| US4961539A (en) | 1989-08-01 | 1990-10-09 | Deem K Michael | Truck-mounted pallet chipper |
| US5747334A (en) | 1990-02-15 | 1998-05-05 | The University Of North Carolina At Chapel Hill | Random peptide library |
| US6162432A (en) | 1991-10-07 | 2000-12-19 | Biogen, Inc. | Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction |
| DE4135070C1 (enExample) | 1991-10-24 | 1993-05-19 | Institut Fuer Rundfunktechnik Gmbh, 8000 Muenchen, De | |
| US6174666B1 (en) | 1992-03-27 | 2001-01-16 | The United States Of America As Represented By The Department Of Health And Human Services | Method of eliminating inhibitory/instability regions from mRNA |
| TW402639B (en) | 1992-12-03 | 2000-08-21 | Transkaryotic Therapies Inc | Protein production and protein delivery |
| US5574138A (en) * | 1993-03-08 | 1996-11-12 | Immunex Corporation | Epithelium-derived T-cell factor |
| US5552303A (en) * | 1993-03-08 | 1996-09-03 | Immunex Corporation | DNA encoding epithelium-derived T-cell factor |
| US6063911A (en) | 1993-12-01 | 2000-05-16 | Marine Polymer Technologies, Inc. | Methods and compositions for treatment of cell proliferative disorders |
| US5686115A (en) | 1993-12-01 | 1997-11-11 | Marine Polymer Technologies, Inc. | Poly-β-1→4-N-acetylucosamine copolymer composition with collagen |
| US5624679A (en) | 1993-12-01 | 1997-04-29 | Marine Polymer Technologies, Inc. | Methods and compositions for poly-β-1-4-N-acetylglucosamine biological barriers |
| US5858350A (en) | 1993-12-01 | 1999-01-12 | Marine Polymer Technologies | Methods and compositions for poly-β-1→4-N-acetylglucosamine cell therapy system |
| US5622834A (en) | 1993-12-01 | 1997-04-22 | Marine Polymer Technologies, Inc. | Method of isolating poly-β-1-4-N-acetylglucosamine from microalgal culture |
| JP3547163B2 (ja) | 1994-03-17 | 2004-07-28 | 雪印乳業株式会社 | 無血清培地を用いた物質生産方法 |
| PT772624E (pt) | 1994-04-06 | 2001-03-30 | Immunex Corp | Interleucina-15 |
| US5591630A (en) | 1994-05-06 | 1997-01-07 | Immunex Corporation | Monoclonal antibodies that bind interleukin-15 receptors |
| US6548065B1 (en) * | 1994-05-06 | 2003-04-15 | Immunex Corporation | Interleukin-15 receptors |
| US20020127201A1 (en) * | 1994-07-01 | 2002-09-12 | Dana-Farber Cancer Institute. | Methods for inhibiting T cell responses by manipulating a common cytokine receptor gamma-chain |
| US7008624B1 (en) * | 1995-02-22 | 2006-03-07 | Immunex Corporation | Antagonists of interleukin-15 |
| US5660824A (en) | 1995-05-24 | 1997-08-26 | Grabstein; Kenneth H. | Muscle trophic factor |
| DE19608813C2 (de) * | 1996-03-07 | 1998-07-02 | Angewandte Gentechnologie Syst | Konjugat zur Beeinflussung von Wechselwirkungen zwischen Proteinen |
| US6451308B1 (en) | 1996-04-26 | 2002-09-17 | Beth Israel Deaconess Medical Center | Antagonists of interleukin-15 |
| US6001973A (en) * | 1996-04-26 | 1999-12-14 | Beth Israel Deaconess Medical Center | Antagonists of interleukin-15 |
| DE69810091T2 (de) | 1997-02-21 | 2003-10-09 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw., Zwijnaarde | Verwendung von interleukin-15 |
| TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
| US6787132B1 (en) * | 1997-12-04 | 2004-09-07 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Combined chemo-immunotherapy with liposomal drugs and cytokines |
| US20040170604A1 (en) * | 1998-07-06 | 2004-09-02 | Tosoh Corporation | IL-6 receptor IL-6 direct fusion protein |
| AU4002001A (en) | 2000-03-01 | 2001-09-12 | Med Immune Inc | High potency recombinant antibodies and method for producing them |
| US6569681B1 (en) | 2000-03-14 | 2003-05-27 | Transkaryotic Therapies, Inc. | Methods of improving homologous recombination |
| US20020022030A1 (en) * | 2000-04-26 | 2002-02-21 | Philippa Marrack | Product and process for regulation of T cell responses |
| DE60138222D1 (de) | 2000-09-14 | 2009-05-14 | Beth Israel Hospital | Modulierung von il-2 und il-15 vermittelten t zellantworten |
| US6818216B2 (en) | 2000-11-28 | 2004-11-16 | Medimmune, Inc. | Anti-RSV antibodies |
| TWI255272B (en) | 2000-12-06 | 2006-05-21 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
| US7041657B2 (en) | 2001-02-12 | 2006-05-09 | Marine Polymer Technologies Inc. | Compositions and methods for modulation of vascular structure and/or function |
| US7638604B2 (en) * | 2001-02-23 | 2009-12-29 | Genetics Institute, Llc | Monoclonal antibodies against interleukin-22 |
| WO2002098370A2 (en) | 2001-03-02 | 2002-12-12 | Medimmune, Inc. | Methods of administering/dosing cd2 antagonists for the prevention and treatment of autoimmune disorders or inflammatory disorders |
| GB0209893D0 (en) | 2002-04-30 | 2002-06-05 | Molmed Spa | Conjugate |
| ATE525398T1 (de) | 2002-05-10 | 2011-10-15 | Medimmune Inc | Epha2 monoklonale antikörper und deren anwendungsverfahren |
| EP1575509B1 (en) | 2002-05-10 | 2011-10-26 | Purdue Research Foundation | Epha2 agonistic monoclonal antibodies and methods of use thereof |
| EP1575601B1 (en) | 2002-12-16 | 2015-07-01 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Recombinant vaccine viruses expressing il-15 and methods of using the same |
| DE10260805A1 (de) * | 2002-12-23 | 2004-07-22 | Geneart Gmbh | Verfahren und Vorrichtung zum Optimieren einer Nucleotidsequenz zur Expression eines Proteins |
| US9068234B2 (en) | 2003-01-21 | 2015-06-30 | Ptc Therapeutics, Inc. | Methods and agents for screening for compounds capable of modulating gene expression |
| EP1601757B1 (en) | 2003-02-24 | 2016-11-30 | Marine Polymer Technologies, Inc. | Cell-polymer fiber compositions and use thereof |
| WO2005023289A1 (ja) | 2003-09-08 | 2005-03-17 | Intellectual Property Consulting Incorporated | 慢性ｃ型肝炎を治療するための医薬組成物 |
| US7435596B2 (en) * | 2004-11-04 | 2008-10-14 | St. Jude Children's Research Hospital, Inc. | Modified cell line and method for expansion of NK cell |
| ES2367027T3 (es) | 2004-02-27 | 2011-10-27 | Inserm (Institut National De La Santé Et De La Recherche Medicale) | Sitio de unión de la il-15 para il-15ralfa y mutantes específicos de il-15 que tienen actividad agonista/antagonista. |
| WO2006017853A2 (en) * | 2004-08-11 | 2006-02-16 | Beth Israel Deaconess Medical Center, Inc. | Mutant interleukin-15-containing compositions and suppression of an immune response |
| JP2008515896A (ja) | 2004-10-05 | 2008-05-15 | オクスナー クリニック ファウンデーション | Ｉｌ−１５によるｂ細胞増殖の増強 |
| CN101061216A (zh) | 2004-11-19 | 2007-10-24 | 比奥根艾迪克Ma公司 | 用于生产哺乳动物细胞的方法 |
| US20060165668A1 (en) * | 2004-12-10 | 2006-07-27 | Liu Linda N | Genetically modified tumor cells as cancer vaccines |
| MX2007009908A (es) | 2005-02-15 | 2007-10-03 | Novartis Vaccines & Diagnostic | Metodos para tratar linfomas utilizando una combinacion de un agente quimioterapeutico e il-2 y opcionalmente un anticuerpo anti-cd20. |
| US20060257361A1 (en) * | 2005-04-12 | 2006-11-16 | Government Of The Us, As Represented By The Secretary, Department Of Health And Human Services | Novel form of interleukin-15, Fc-IL-15, and methods of use |
| PL1899364T5 (pl) * | 2005-05-17 | 2024-12-09 | University Of Connecticut | Kompozycje i sposoby immunomodulacji w organizmie |
| EP1777294A1 (en) | 2005-10-20 | 2007-04-25 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins |
| WO2007070488A2 (en) | 2005-12-12 | 2007-06-21 | The Cbr Institute For Biomedical Research, Inc. | Integrin alpha l i domain mutants with increased binding affinity |
| US20070160578A1 (en) * | 2005-12-14 | 2007-07-12 | The Gov. Of The Usa As Represented By The Secretary Of The Dep. Of Health And Human Services | Expansion of natural killer and CD8 T-cells with IL-15R/ligand activator complexes |
| EP1984505B1 (en) | 2006-01-13 | 2019-12-25 | The Government of the U.S.A., as repr. by the Secretary, Dept. of Health & Human Services, the Nat. Inst. of Health | Codon optimized il-15 and il-15r-alpha genes for expression in mammalian cells |
| CN101573139A (zh) | 2006-02-16 | 2009-11-04 | 纳森特生物制剂公司 | 在哺乳动物个体中改善免疫功能的方法以及预防或治疗疾病的方法 |
| US8586055B2 (en) | 2007-01-12 | 2013-11-19 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | DNA immunization protocols |
| DK2160401T3 (da) | 2007-05-11 | 2014-10-20 | Altor Bioscience Corp | Fusionsmolekyler og il-15-varianter |
| CA2691785C (en) | 2007-06-27 | 2017-01-10 | Marine Polymer Technologies Inc. | Complexes of il-15 and il-15ralpha and uses thereof |
| EP3135294B1 (en) | 2009-08-14 | 2020-06-03 | The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services | Use of il-15-il-15 receptor heterodimers to treat lymphopenia |
| EP2619229B1 (en) | 2010-09-21 | 2016-04-06 | Altor BioScience Corporation | Multimeric il-15 soluble fusion molecules and methods of making and using same |
| EP2537933A1 (en) | 2011-06-24 | 2012-12-26 | Institut National de la Santé et de la Recherche Médicale (INSERM) | An IL-15 and IL-15Ralpha sushi domain based immunocytokines |
-
2008
- 2008-06-27 CA CA2691785A patent/CA2691785C/en active Active
- 2008-06-27 WO PCT/US2008/008084 patent/WO2009002562A2/en not_active Ceased
- 2008-06-27 EP EP13195499.2A patent/EP2724728B1/en not_active Revoked
- 2008-06-27 EP EP08779855.9A patent/EP2173378B1/en active Active
- 2008-06-27 NZ NZ703668A patent/NZ703668A/en unknown
- 2008-06-27 NZ NZ582330A patent/NZ582330A/en unknown
- 2008-06-27 EP EP13195495.0A patent/EP2724727A1/en not_active Withdrawn
- 2008-06-27 ES ES13195499T patent/ES2716476T3/es active Active
- 2008-06-27 US US12/666,052 patent/US9931377B2/en active Active
- 2008-06-27 DK DK08779855.9T patent/DK2173378T3/da active
- 2008-06-27 ES ES08779855.9T patent/ES2466916T3/es active Active
- 2008-06-27 JP JP2010514839A patent/JP2010531878A/ja active Pending
- 2008-06-27 NZ NZ61625408A patent/NZ616254A/en unknown
- 2008-06-27 NZ NZ599338A patent/NZ599338A/xx unknown
- 2008-06-27 AU AU2008269032A patent/AU2008269032B2/en active Active
-
2009
- 2009-12-27 IL IL202997A patent/IL202997A/en active IP Right Grant
-
2014
- 2014-01-08 JP JP2014001373A patent/JP2014114294A/ja active Pending
- 2014-10-29 HK HK14110832.5A patent/HK1198421A1/en unknown
-
2015
- 2015-06-08 JP JP2015115431A patent/JP2015212270A/ja active Pending
-
2016
- 2016-11-22 JP JP2016226503A patent/JP2017079745A/ja not_active Withdrawn
-
2017
- 2017-02-03 US US15/424,621 patent/US10265382B2/en active Active
-
2018
- 2018-12-27 JP JP2018245439A patent/JP2019088288A/ja not_active Withdrawn
-
2019
- 2019-03-04 US US16/291,561 patent/US11110150B2/en active Active
-
2021
- 2021-05-21 JP JP2021086283A patent/JP2021152017A/ja active Pending
-
2022
- 2022-10-28 JP JP2022172896A patent/JP2023015158A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Gong et al. | In situ PEGylation of CAR T cells alleviates cytokine release syndrome and neurotoxicity | |
| RU2487723C2 (ru) | Химерные и гуманизированные антитела к cd44, которые опосредствуют цитотоксичность в отношении раковых клеток | |
| ATE481483T1 (de) | Verfahren zur herstellung eines rekombinanten polyklonalen proteins | |
| WO2009014708A3 (en) | Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof | |
| EA201590631A1 (ru) | Антигенсвязывающие белки, способные связывать тимусный стромальный лимфопоэтин | |
| MX2011006422A (es) | Autoanticuerpos humanos anti-alfa-sinucleina. | |
| HRP20211582T1 (hr) | Protutijela specifična za tgf-beta | |
| NZ717429A (en) | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly | |
| EP4289944A3 (en) | Method for preparing genetically-modified t cells which express chimeric antigen receptor | |
| MX2010008570A (es) | Anticuerpos alfa5-beta1 y sus usos. | |
| RU2012143793A (ru) | Биспецифические двухвалентные антитела анти-vegf/анти-ang-2 | |
| Huang et al. | CAR-macrophage: breaking new ground in cellular immunotherapy | |
| JP2011504099A5 (enExample) | ||
| Xia et al. | Engineering a HER2-CAR-NK cell secreting soluble programmed cell death protein with superior antitumor efficacy | |
| WO2007067744A3 (en) | Method for assembling a polymer-biologic delivery composition | |
| Gomzikova et al. | Mesenchymal stem cell derived biocompatible membrane vesicles demonstrate immunomodulatory activity inhibiting activation and proliferation of human mononuclear cells | |
| Xiao et al. | Natural killer cells: a promising kit in the adoptive cell therapy toolbox | |
| Passariello et al. | Novel bi-specific immuno-modulatory tribodies potentiate T cell activation and increase anti-tumor efficacy | |
| Mishra et al. | Revolutionizing cancer treatments through stem cell-derived CAR T cells for immunotherapy: opening new horizons for the future of oncology | |
| Ren et al. | Translational models in glioma immunotherapy research | |
| Matarneh et al. | Regulatory T cell in kidney transplant: the future of cell therapy? | |
| Santoro et al. | Cell Surface Markers of Mesenchymal Stem Cells: Current Knowledge and Advances in Characterization Technologies | |
| Ebbinghaus et al. | Endogenous signaling molecule activating (ESMA) CARs: A novel CAR design showing a favorable risk to potency ratio for the treatment of triple negative breast cancer | |
| Fagoonee et al. | The Role of Extracellular Vesicles in Mediating Signaling in Biliary Epithelial Cell Activation and Cholangiopathies | |
| Zhang et al. | Interleukin 21-Armed EGFR-VHH-CAR-T Cell Therapy for the Treatment of Esophageal Squamous Cell Carcinoma |